Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pyridones | 1 | 2021 | 42 | 0.680 |
Why?
|
| HIV-1 | 3 | 2025 | 723 | 0.670 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 137 | 0.650 |
Why?
|
| CD40 Antigens | 1 | 2019 | 60 | 0.610 |
Why?
|
| CD40 Ligand | 1 | 2019 | 159 | 0.610 |
Why?
|
| Antibodies, Neutralizing | 4 | 2025 | 214 | 0.580 |
Why?
|
| Epitopes | 1 | 2019 | 292 | 0.560 |
Why?
|
| HIV Infections | 4 | 2025 | 976 | 0.490 |
Why?
|
| Macaca mulatta | 5 | 2025 | 256 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 870 | 0.450 |
Why?
|
| HIV Antibodies | 2 | 2025 | 148 | 0.420 |
Why?
|
| Simian Immunodeficiency Virus | 2 | 2024 | 81 | 0.390 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2024 | 59 | 0.230 |
Why?
|
| Abatacept | 1 | 2025 | 66 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2025 | 109 | 0.220 |
Why?
|
| Immunization, Passive | 1 | 2024 | 96 | 0.220 |
Why?
|
| Mutation | 2 | 2021 | 2629 | 0.180 |
Why?
|
| Diketopiperazines | 1 | 2021 | 2 | 0.180 |
Why?
|
| HIV Integrase | 1 | 2021 | 7 | 0.180 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2021 | 28 | 0.170 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 24 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 104 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 116 | 0.160 |
Why?
|
| Granuloma | 1 | 2019 | 43 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 156 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 198 | 0.150 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2019 | 365 | 0.150 |
Why?
|
| Dependovirus | 1 | 2025 | 721 | 0.150 |
Why?
|
| Interleukin-10 | 1 | 2019 | 161 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2019 | 229 | 0.150 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 571 | 0.140 |
Why?
|
| Protein Conformation | 1 | 2019 | 785 | 0.120 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 1597 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2019 | 303 | 0.120 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2019 | 416 | 0.110 |
Why?
|
| Animals | 6 | 2025 | 20962 | 0.110 |
Why?
|
| Lung | 1 | 2019 | 964 | 0.110 |
Why?
|
| Inflammation | 1 | 2019 | 1162 | 0.100 |
Why?
|
| Humans | 5 | 2024 | 64243 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2238 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 76 | 0.050 |
Why?
|
| Sirolimus | 1 | 2022 | 94 | 0.040 |
Why?
|
| Lymphocryptovirus | 1 | 2021 | 1 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 125 | 0.040 |
Why?
|
| Viral Load | 1 | 2022 | 233 | 0.040 |
Why?
|
| Virus Replication | 1 | 2022 | 323 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 374 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2019 | 48 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 79 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 329 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2025 | 889 | 0.040 |
Why?
|
| Immunity | 1 | 2019 | 107 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 429 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 645 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 1001 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2176 | 0.030 |
Why?
|
| Male | 1 | 2025 | 30295 | 0.010 |
Why?
|